A novel route to the racemic selenide (1RS,12bRS)-1-ethyl-2, 3,6,7,12,12b-hexahydro-1-[2-(phenylseleno)ethyl]indolo[2,3-a]quinolizin-4(1H)-one (13b), a key intermediate in the total synthesis of vallesamidine (1), was elaborated. Compound 3a, obtained by Pictet-Spengler reaction of tryptamine and cyclohept-4-enyl-1-carbaldehyde (2c), was oxidized with KMnO 4 to the diacid 4, which was subsequently converted into the isomeric tetracyclic lactams 5a,b. After proper protection maneuvers, Barton decarboxylation of 10a,b, trapping with PhSe 2 Ph, and Boc removal afforded 13b.
precursor of vallesamidine (1) [12d]. Hence, with this protocol, a formal synthesis of 1 in its racemic form was established.
Since the cyclization of 13b was carried out via homolysis of the CÀSe bond, we attempted the Barton decarboxylation of 10b without radical interceptor, but did not observe any pentacyclic product. We must attribute this failure to the presence of the N-Boc group.
In our previous work on an approach to eburnamonine, we had employed a cyclopent-3-enylcarbaldehyde to construct a tetrahydro-b-carboline intermediate, and cleavage of the C=C bond released two C 2 chains for the eventual transformation into an Et group and elements of the lactam ring. The present report describes the use of a cyclohept-4-enylcarbaldehyde, but it provided skeletal atoms for both rings D and E of vallesamidine.
We thank the National Science Council, Republic of China, for financial support.
Experimental Part
General. All reactions were conducted under N 2 ; workup solns. were dried over Na 2 2 NH in 20 ml of anh. THF) at À 788 was slowly added a soln. of ethyl cyclohept-4-ene-1-carboxylate (2.0 g, 11.9 mmol) in THF (5 ml), followed by a soln. of EtBr (1.63 g, 15 mmol) in THF (5 ml) after 30 min. After an additional 1 h, the mixture was warmed to r.t. and kept overnight. After quenching with sat. aq. NH 4 Cl soln. (20 ml), the product was extracted with Et 2 O, the combined org. solns. were washed with brine, dried (Na 2 SO 4 ), and evaporated. The resulting residue was subjected to CC (AcOEt/hexane 1 : 19): 2a ( [3,4-b] indole (3a). A soln. of 2c (0.15 g, 1.0 mmol) in anh. CH 2 Cl 2 (3 ml) was mixed with a soln. of tryptamine (0.18 g, 1.1 mmol) in CH 2 Cl 2 (3 ml), and this mixture was stirred at r.t. overnight. On cooling to 08, the mixture was treated with a soln. of CF 3 COOH (TFA; 5.0 mmol, 0.4 ml) in CH 2 Cl 2 (2 ml) over 10 min. After 1 h, the ice bath was removed, the mixture was kept overnight, and poured into ice-cold 5% aq. NaHCO 3 soln. (50 ml). Workup involved layer separation, extraction with CH 2 Cl 2 , washing with aq. NaHCO 3 soln. and brine, drying, evaporation, and CC (AcOEt/hexane 1 : 5 ! 9 : 5): 3a (0.12 g, 61% [3,4-b] indole-2,9-dicarboxylate (3b). Compound 3a (0.10 g, 0.34 mmol) was mixed with (Boc) 2 O (0.25 g, 1.18 mmol) and DMAP 2 ) (0.01 g, 0.02 mmol) in CH 2 Cl 2 (5 ml), and stirred at 508 overnight. Workup involved dilution with CH 2 Cl 2 (5 ml), washing with brine, drying, evaporation, and CC (AcOEt/hexane 1 : 1): 3b (0.11 g, 60%; two isomers). Thick oil. IR: 1734, 1691 (C=O). [2,3-a] quinolizine-12(2H)-carboxylate (5b). To an ice-cooled, stirred mixture of 3b (200 mg, 0.40 mmol), Bu 4 NBr (20 mg, 0.06 mmol) in THF (2.0 ml), and H 2 O (12.0 ml) was added KMnO 4 (320 mg, 2.0 mmol) in several lots over 30 min. Another portion of H 2 O (3.0 ml) was added, and the mixture was warmed to r.t. Excess oxidant was destroyed with Na 2 SO 3 (250 mg, 2.0 mmol), the mixture was diluted with CH 2 Cl 2 (15 ml), filtered through a pad of Celite, and evaporated. The solid residue was taken up in CH 2 Cl 2 (15 ml), and the soln. was washed with brine, dried, and evaporated to afford the diacid 4, which was immediately refluxed with TsOH (10 mg, 0.05 mmol) in CHCl 3 (7.5 ml) and EtOH (5.0 ml) for 18 h. Workup involved dilution with CH 2 Cl 2 (15 ml), layer separation, washing with brine, drying, evaporation and CC (AcOEt/hexane gradient: 1 : 5 ! 9 : 5) to afford the trans-and cis-isomers 5a (40 mg, 21%) and 5b (30 mg, 16%), resp.
Data of 5a. (1RS,12bSR)-1-Ethyl-1,3,4,6,7,12b-hexahydro-4-oxo-1-[3-oxo-3-(phenylmethoxy) (1RS,12bRS)-1-Ethyl-1,3,4,6,7,12b-hexahydro-4-oxo-1-[3-oxo-3-(phenylmethoxy) propyl]-indolo [2,3-a] 1-ethyl-1,3,4,6,7,12b-hexahydro-4-oxoindolo [2,3-a] quinolizine-12(2H)-carboxylate (11a). To a stirred, ice-cooled mixture of 10a (50 mg, 0.113 mmol) in THF (3.0 ml) and N-methylmorpholine (40 mg, 0.40 mmol) in THF (1 ml) was added ethyl chloroformate (40 mg, 0.37 mmol) in THF (1 ml). After 30 min, solns. of Et 3 N (40 mg, 0.40 mmol) in CCl 4 (2 ml) and N-hydroxy-2-thiopyridone (40 mg, 0.31 mmol) in CCl 4 (3 ml) were added consecutively. After another 30 min, the yellow-colored mixture was cooled in an ice bath, and irradiated at 300 nm with a Rayonet photochemical apparatus for 1 h. Workup involved dilution with CH 2 Cl 2 (10 ml), washing with 5% aq. 
